GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to wipe out stomach tumors before surgery
Disease control Not yet recruitingThis study tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy and a targeted therapy can shrink locally advanced stomach or gastroesophageal junction cancer in patients with specific genetic markers (MSI-H/dMMR). The goal is to…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 26, 2026 10:57 UTC
-
New drug cocktail aims to shrink stomach tumors in First-Line trial
Disease control Not yet recruitingThis study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy as a first treatment for people with advanced HER2-negative stomach or gastroesophageal junction cancer. The goal is to see if this approach can delay cancer growth and …
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 26, 2026 10:49 UTC
-
Triple threat: new combo aims to shrink stomach tumors before surgery
Disease control Not yet recruitingThis study tests whether adding low-dose radiation and an immunotherapy drug (tislelizumab) to standard chemotherapy before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 adults aged 20-80 with resectable tumor…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 26, 2026 10:49 UTC